ESTABLISHMENT LABS HOLDINGS INC.: management transactions · United States · SEC (Form 4)

About ESTABLISHMENT LABS HOLDINGS INC.

Establishment Labs Holdings Inc. (NASDAQ: ESTA) is a medical technology company headquartered in the United States with a business model centered on women’s health, particularly breast aesthetics and breast reconstruction. Founded by Juan José Chacón-Quirós, the company built its industrial base in Costa Rica, where its operational headquarters and main manufacturing capabilities are located in Alajuela. Establishment Labs has grown into a global business, with products distributed in more than 100 countries, and it markets directly to plastic and reconstructive surgeons as well as other healthcare providers. ([investors.establishmentlabs.com](https://investors.establishmentlabs.com/press-releases/press-releases-details/2025/Establishment-Labs-to-Present-at-the-43rd-Annual-J.P.-Morgan-Healthcare-Conference/default.aspx?utm_source=openai)) The company’s core franchise is the Motiva family of silicone breast implants and related breast-health solutions. Its portfolio includes proprietary technologies such as SmoothSilk and Ergonomix, which are designed to enhance biocompatibility, softness, and a more natural response to body movement. Over time, Establishment Labs has broadened beyond standard implants into a more differentiated minimally invasive platform, including Mia Femtech and Preservé, as well as Motiva Flora, a tissue expander used in breast reconstruction. This combination gives the company exposure to both aesthetic and reconstructive procedures, two markets with attractive long-term demand drivers. ([investors.establishmentlabs.com](https://investors.establishmentlabs.com/press-releases/press-releases-details/2025/Establishment-Labs-Launches-Preserv/default.aspx?utm_source=openai)) From a competitive standpoint, Establishment Labs positions itself as an innovation-led challenger in a category historically dominated by larger legacy players. Its regulatory progress in the United States is a major strategic milestone: FDA approval for Motiva helped unlock the largest medical device market and strengthened the brand’s credibility with surgeons and patients. U.S. commercial momentum is now visible in reported quarterly results, which show growing Motiva sales in the United States as the company scales its domestic launch. ([investors.establishmentlabs.com](https://investors.establishmentlabs.com/press-releases/press-releases-details/2024/Establishment-Labs-Receives-U.S.-FDA-Approval-for-Motiva-Implants/default.aspx?utm_source=openai)) Recent news has been constructive. In 2025, the company launched Preservé in Brazil and continued rolling it out internationally, while also reporting improving revenue trends and expanding guidance. In early 2026, quarterly revenue increased further and management raised full-year expectations. The company also announced in April 2026 that more than five million Motiva devices had been placed in the market, underscoring commercial penetration and long-term installed-base growth. For investors, ESTA is best viewed as a NASDAQ-listed United States healthcare growth story driven by product innovation, geographic expansion, and regulatory execution. ([investors.establishmentlabs.com](https://investors.establishmentlabs.com/press-releases/press-releases-details/2025/Establishment-Labs-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results-and-Reaffirms-2025-Guidance/default.aspx?utm_source=openai))